DUBLIN--(BUSINESS WIRE)--The "Chronic Respiratory Disease Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.
This report Chronic Respiratory Disease Drug Development Pipeline Review, 2018, provides an overview of the pipeline landscape for chronic respiratory diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).
There are 187 products in development for this indication. IPF is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. There are 136 products in development for this indication.
Molecular targets in development for chronic respiratory diseases include phosphodiesterases, adrenergic receptors, interleukins and chemokine receptors. Companies operating in this pipeline space include AstraZeneca, GlaxoSmithKline and Galapagos.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Key Topics Covered:
1 Introduction
2 Therapeutics Development
3 Therapeutics Assessment
4 Companies Involved in Therapeutics Development
5 Dormant Projects
6 Discontinued Products
7 Product Development Milestones
8 Appendix
For more information about this report visit https://www.researchandmarkets.com/research/q4hft9/chronic?w=4
